The Medtronic Linq and Linq II implantable cardiac monitors (ICMs) have become some of the most popular ICM devices on the market. Part of the reason is their ability to be quickly inserted under the skin in seconds. This is a quick demonstration of the implant procedure at the vendor's booth at ACC.22.
The Linq II insertable cardiac monitoring system offers an extended battery life for 4.5 years of monitoring. The Reveal Linq device provides about 3 years of battery life.
The Linq II device also offers Bluetooth connectivity with the patient's smartphone to increase real-time monitoring away from the base station. This automatically allows event notification triggers and actionable alerts. The system also allows remote programming of the cardiac monitor so the patient does not need to come into the office.
ICMs are used for longer term cardiac monitoring to help diagnose patients with symptoms of transient arrhythmias. They are often used in patients with cryptogenic stroke and transient ischemic attack to determine if the patient has atrial fibrillation or other heart rhythm issues.
Related Implantable Cardiac Monitor Content:
Medtronic gains FDA approval for AI models focused on cardiac monitoring
Medtronic’s new ICM gains FDA clearance, CE mark approval
Dave Fornell has covered healthcare for more than 17 years, with a focus in cardiology and radiology. Fornell is a 5-time winner of a Jesse H. Neal Award, the most prestigious editorial honors in the field of specialized journalism. The wins included best technical content, best use of social media and best COVID-19 coverage. Fornell was also a three-time Neal finalist for best range of work by a single author. He produces more than 100 editorial videos each year, most of them interviews with key opinion leaders in medicine. He also writes technical articles, covers key trends, conducts video hospital site visits, and is very involved with social media. E-mail: dfornell@innovatehealthcare.com